Usami E - Search Results

1

Alternative palbociclib dosing schedules for hormone receptor-positive and HER2-negative metastatic breast cancer.

Go M, Kimura M, Yamada S, Kamei K, Noguchi Y, Usami E, Yoshimura T. Go M, et al. Among authors: usami e. Oncology. 2024 Dec 11:1-22. doi: 10.1159/000542991. Online ahead of print. Oncology. 2024. PMID: 39662069

2

Impact of pharmacist-led aminoglycoside stewardship: a 10-year observational study.

Shinoda Y, Ohashi K, Matsuoka T, Arai K, Hotta N, Usami E. Shinoda Y, et al. Among authors: usami e. J Pharm Health Care Sci. 2024 Nov 28;10(1):77. doi: 10.1186/s40780-024-00399-x. J Pharm Health Care Sci. 2024. PMID: 39609916 Free PMC article.

3

Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective Study.

Mori K, Kimura M, Usami E. Mori K, et al. Among authors: usami e. Cureus. 2024 Oct 8;16(10):e71049. doi: 10.7759/cureus.71049. eCollection 2024 Oct. Cureus. 2024. PMID: 39512953 Free PMC article.

4

Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma.

Kimura M, Yamada S, Go M, Yasuda S, Toyoda H, Usami E. Kimura M, et al. Among authors: usami e. J Oncol Pharm Pract. 2024 Sep 23:10781552241281900. doi: 10.1177/10781552241281900. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 39311154

5

Pharmacist-initiated interventions to test quantitative bone mineral density and prescribe osteoporosis medications to prevent steroid-induced osteoporosis.

Hirose T, Mori K, Kimura M, Yamashita S, Hayashi H, Usami E, Tanase T. Hirose T, et al. Among authors: usami e. Pharmazie. 2024 Jun 1;79(6):124-128. doi: 10.1691/ph.2024.4510. Pharmazie. 2024. PMID: 38877679

6

Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment.

Kimura M, Yamada S, Go M, Yasuda S, Toyoda H, Usami E. Kimura M, et al. Among authors: usami e. Oncol Lett. 2024 May 17;28(1):330. doi: 10.3892/ol.2024.14464. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38807665 Free PMC article.

7

Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study.

Noguchi Y, Asano H, Masuda R, Teshigawara Y, Go M, Kimura M, Usami E, Yoshimura T. Noguchi Y, et al. Among authors: usami e. Oncology. 2024;102(11):996-1003. doi: 10.1159/000539426. Epub 2024 May 20. Oncology. 2024. PMID: 38768582

8

Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer.

Go M, Kimura M, Yamada S, Usami E, Noguchi Y, Yoshimura T. Go M, et al. Among authors: usami e. J Pharm Pract. 2024 Dec;37(6):1258-1266. doi: 10.1177/08971900241247653. Epub 2024 Apr 23. J Pharm Pract. 2024. PMID: 38652858

9

Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.

Go M, Noguchi Y, Masuda R, Asano H, Kimura M, Usami E, Yoshimura T. Go M, et al. Among authors: usami e. Int J Cancer. 2024 Sep 1;155(5):849-853. doi: 10.1002/ijc.34962. Epub 2024 Apr 15. Int J Cancer. 2024. PMID: 38619193

10

Vancomycin-Induced Neutropenia With Subsequent Perioperative Readministration: A Case Report.

Shinoda Y, Kawabata T, Ohashi K, Usami E. Shinoda Y, et al. Among authors: usami e. Cureus. 2024 Mar 9;16(3):e55858. doi: 10.7759/cureus.55858. eCollection 2024 Mar. Cureus. 2024. PMID: 38590472 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters